Oxurion NV Logo

Oxurion NV

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oxurion NV is a biopharmaceutical company undergoing a strategic transition. Historically, the company focused on pioneering treatments for retinal diseases, such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD), using innovative approaches including a CRISPR-based target discovery platform. Following a recent strategic shift, Oxurion has ended its internal R&D program in Geographic Atrophy to refocus its business on providing Contract Research Organization (CRO) services to the life sciences sector.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oxurion NV. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 18:00
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
English 195.7 KB
2025-08-07 18:00
Regulatory News Service
FR_OXURION_PR_New-Development-Strategy_SD_20250806.pdf
French 133.2 KB
2025-08-07 18:00
Earnings Release
OXUR-New-Development-Strategy-NL-20250806.pdf
Dutch 213.8 KB
2025-08-07 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250807.pdf
English 479.6 KB
2025-08-07 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250807.pdf
English 506.8 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_UK.pdf
English 200.6 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_FR.pdf
French 157.5 KB
2025-08-04 08:30
M&A Activity
OXURION_PR_Closing_Acquisition_NL.pdf
Dutch 246.7 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250723.pdf
English 358.7 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250723.pdf
Dutch 381.8 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250730.pdf
English 360.1 KB
2025-07-30 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250730.pdf
Dutch 383.3 KB
2025-07-30 18:00
Share Issue/Capital Change
OXUR-PR_Voting-rights-ENG_20250730.pdf
English 281.6 KB
2025-07-30 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-NED_20250730.pdf
Dutch 405.2 KB
2025-07-25 18:00
Declaration of Voting Results & Voting Rights Announcements
OXUR-PR_Voting-rights-ENG_20250725.pdf
English 281.3 KB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiopharmaceuticals like Radspherin® for localized cancer treatment.
Norway OCIN
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
Onxeo Logo
Developing precision therapies for complex diseases using a proprietary single-domain antibody platform.
France ALONX
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
Oramed Pharmaceuticals Inc. Logo
Developing oral drug delivery systems to replace injections, like an oral insulin capsule.
Israel ORMP
Oryzon Genomics S.A. Logo
Advancing epigenetic therapeutics for oncology and central nervous system disorders.
Spain ORY
OSE Immunotherapeutics Logo
Developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation.
France OSE
Ovoca Bio Plc Logo
Clinical-stage biopharma developing novel treatments for female sexual dysfunction.
Ireland OVXA